Compare Morgan Stanley (MS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Summit Therapeutics Inc — how do they compare? Morgan Stanley trades at $216.38 (market cap $331.60B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Morgan Stanley is far larger — about 31.6× Summit Therapeutics Inc's market cap, and Morgan Stanley pays a 2.18% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MS | SMMT | |
|---|---|---|
Market Cap | $331.60B | $10.48B |
Sector | Financials | Health |
52-Week High | $228.42 | $29.32 |
52-Week Low | $139.09 | $13.05 |
Dividend Yield | 2.18% | — |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.48, down 1.33% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $66.0B in 2025, with net income reaching $16.9B and a profit margin of 25.6%. The stock has beaten earnings estimates for three consecutive quarters, and analysts maintain a consensus buy rating with a $241.36 price target. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook for MS is positive, driven by earnings momentum and strategic initiatives like AI adoption and high-profile IPOs. Risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to the consensus target, but investors should monitor execution on growth initiatives and macroeconomic impacts on financial services.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
